fr   en
Clinical Studies
Phase :    
Announcement :   
Select a Pharma :
Select a product :
Select a disease :
Choose date:
[<<]      «      5   |   6   |   7   |   8   |   9   |   10   |   11   |   12   |   13   |   14   |   15      »      [57]
Date Phase Anouncement Biotech Pharma Product Disease Country Other
2009-12-15 I-IIa Launch Biovitrum (Sweden)   rFVIIIFc protein (long-acting fully-recombinant Factor VIII Fc fusion protein) hemophilia A   See details
2009-12-15 II Launch BioAlliance Pharma (France)   clonidine Lauriad® oral mucositis France See details
2009-12-15 II-III Launch Cardio3 BioSciences (Belgium)   C-Cure® This second-generation cell therapy allows differentiation of patients' own bone marrow stem cells into cardiopoietic cells able to generate new cardiac cells and repair damaged cardiac muscle. This therapy is based on technology produced by the Mayo Clinic in the United States and was developed by clinicians at the Alost Cardiovascular Centre (Belgium) founded by Cardio3 Biosciences in 2007 heart failure Belgium, Servia See details
2009-12-15 I Launch BioAlliance Pharma (France)   AMEP® Its mechanism of action targets specific receptors involved in tumor growth and in tumor angiogenesis. invasive melanoma Denmark, Slovenia See details
2009-12-14 I Launch Ablynx (Belgium)   ALX-0141 This Nanobody® is targeting Receptor Activator of Nuclear Factor kappa B Ligand (RANKL), which is involved in the production of osteoclasts, a type of cell responsible for bone resorption. degenerative bone diseases, such as post-menopausal osteoporosis, rheumatoid arthritis and cancer driven bone deterioration.   See details
2009-12-14 I Result   Ipsen (France) BN83495 (first-in-class orally available irreversible steroid sulfatase (STS) inhibitor) The compound is currently in further clinical development for advanced endometrial cancer (phase II) as well as in Phase I clinical evaluation for castrate resistant prostate cancer in North America (see estrogen receptor (ER) positive metastatic breast cancer France, Belgium and UK See details
2009-12-10 III Result BioAlliance Pharma (France)   acyclovir Lauriad® recurrent herpes labialis in immunocompetent patients International and multicenter trial See details
2009-12-10 III Launch   Merck KGaA (Germany) Stimuvax® (BLP25 liposome vaccine) This therapeutic cancer vaccine has been designed to stimulate the body's immune system to identify and target cancer cells that express MUC1, an antigen commonly expressed in non-small cell lung cancer as well as in other common cancer types such as breast cancer, multiple myeloma, colorectal, prostate and ovarian cancers. advanced non-small cell lung cancer China, Hong Kong, South Korea, Singapore and Taiwan See details
2009-12-08 II Result BioAlliance Pharma (France)   Doxorubicin Transdrug® advanced hepatocellular carcinoma   See details
2009-12-08 I Launch Galapagos (Belgium) GSK (UK) GLPG0555 arthritis Belgium See details
2009-12-08 I-IIa Launch Cytheris (France)   CYT107 (recombinant glycosylated interleukin-7/IL-7) chronic hepatitis B France, Italy See details
2009-12-08 IIa Result Actelion (Switzerland)   ACT-128800 (Sphingosine-1-phosphate (S1P1) receptor agonist) psoriasis, multiple sclerosis   See details
2009-12-08 II Launch Neovacs (France)   TNF alpha-kinoid (heterocomplex formed from an inactivated targeted cytokine (TNF alpha) and a carrier protein, KLH) rheumatoid arthritis France, Belgium, Switzerland See details
2009-12-07 I-II Result BiondVax Pharmaceuticals (Israel)   multimeric-001 universal flu vaccine flu Israel See details
2009-12-07 II Result Antisoma (UK)   AS1413 (DNA intercalator) secondary acute myeloid leukaemia   See details
[<<]      «      5   |   6   |   7   |   8   |   9   |   10   |   11   |   12   |   13   |   14   |   15      »      [57]